Mar 10, 2023 15:04 JST

Source: Eisai

Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award

TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win).

The "J-Win Diversity Award" has been held annually since 2008 with the aim of accelerating the promotion of diversity and inclusion (D&I) in Japanese companies by awarding leading businesses that are promoting D&I. Among the Company Prizes, Eisai was selected as the winner of the "Basic Achievement Grand Prize", which is the highest award within the "Basic Category" covering businesses who demonstrate the significance and purpose of female empowerment, developing systems and frameworks with set goals, and are taking action as a first step towards D&I promotion.

 


Reasons For Award-Winner Selection

Promoting D&I by viewing acquisition of diverse human talents and their successes as essential for realizing their corporate concept. While promoting company-wide initatives with the "DE&I (Diversity, Equity & Inclusion) Promotion Committee", encouraging independent activities appropriate to onsite challenges through "DE&I projects" at each department. Further expansion in the number of female managers is expected down the road.

Highly Regarded Measures/Initiatives
1) Top management commitment and promotional framework for D&I
- Promoting D&I by regarding acquisition and retention of diverse human talents and their successes as essential to evolve the "hhc (human health care)" concept and realize an "hhceco company"
- Promoting activities by division, setting up "DE&I Projects" for global functions, such as corporate, R&D and manufacturing operations as well as each regional function, in parallel with implementing the "DE&I Promotion Committee" throughout the company.
- Plans to introduce a new personnel assessment system from FY 2023, which utilizes a behavioral assessment item "Diversity & Synergy" to further focus on diversity.

2) Developing female leaders
- Implementing E-Win (Eisai Women's Innovative Network) program to encourage personal growth and foster career awareness/aspirations

3) Reforming corporate culture/promoting increased awareness
- Promoting dialogues within the organization by leveraging monthly engagement survey

Eisai's corporate concept (also known as the hhc Concept) is to give first thought to patients and the people in the daily living domain, and increase the benefits that healthcare provides to them as well as meet their diversified healthcare needs worldwide. Eisai aims to realize the spiral of knowledge generated by diversity, regardless of differences in nationality, gender, age, etc., leading to the creation of innovation. Eisai also acquired third party appraisals including "Platinum Kurumin", an accreditation for organizations implementing high level parenting support by Ministry of Health, Labour and Welfare, as well as "the New Diversity Management Selection 100" and "Health & Productivity Management Outstanding Organizations" by Ministry of Economy, Trade and Industry.

Eisai is promoting DE&I throughout the company to ensure it has the diversity to meet increasingly diverse needs of patients and the people in the daily living domain.

For more information about Eisai's DE&I promotion, please visit it's corporate website.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

For more information, visit www.eisai.com/news/2023/news202318.html.

Source: Eisai
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
June 08 2023 12:32 JST
 
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
June 02 2023 11:20 JST
 
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26 2023 13:15 JST
 
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25 2023 20:02 JST
 
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24 2023 17:03 JST
 
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 20 2023 09:20 JST
 
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
May 16 2023 08:27 JST
 
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
May 08 2023 10:15 JST
 
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
April 06 2023 17:32 JST
 
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
April 04 2023 12:23 JST
 
More Press release >>

Latest Press Release


More Latest Release >>